Kontrol Technologies Corp. Q1 FY2021 Earnings Call
· Earnings call transcript and AI-powered summary
- Revenue: $3.3M for Q1 2021, representing a 20% increase compared to Q1 2020. Q1 results were impacted by project delays due to Ontario lockdowns (~$500K in deferred revenue now expected in Q3–Q4).
- Adjusted EBITDA: $1.1M in Q1 2021, up from $241K in Q1 2020—a 356% year-over-year increase.
- Operating Cash Flow: $593K in Q1 2021, improving by $610K over Q1 2020 (which recorded a negative $17K).
- BioCloud Investment: $4M invested as of Q1 2021 in R&D and pre-commercialization.
- Balance Sheet Improvements:
- $631K in convertible debentures converted to equity in Q1 2021.
- $710K raised from option and warrant exercises.
- Approximately $922K in debentures extended to mature in October 2022.
- New Institutional Capital: Announced $8.5M private placement with U.S. institutional investors (closing expected around June 1, 2021). Funding supports supply chain optimization and BioCloud production scalability.
- BioCloud Update:
- Two units shipped to Health Canada for post-manufacturing lab testing; results expected July 2021.
- Exclusive distributor agreement signed with Royal Health Group in UAE following a successful pilot.
Continue Reading
Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.
Upgrade to ProfessionalContinue Reading
Unlock the full earnings call transcript with speaker labels and formatted dialogue.
Upgrade to Professional